Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03895684 · ClinicalTrials.gov registry record · Phase 1

Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Salarius Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
23
Enrollment target
2
Study locations

NCT03895684 is a Phase 1 study of Advanced Solid Tumors that has completed, run by Salarius Pharmaceuticals. The registered enrollment target is 23 participants, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03895684, a Phase 1 study of Advanced Solid Tumors, has completed, sponsored by Salarius Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
23 participants
Enrollment target
2
Study locations

Study Summary

Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG SP-2577 Seclidemstat

Study Locations (2)

Arizona

  • HonorHealth - Scottsdale

California

  • Sarcoma Oncology Research Center - Santa Monica

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2019-06-25
Est. Completion 2021-04-13
Phase Phase 1

Sponsor

Salarius Pharmaceuticals

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03895684

The ClinicalTrials.gov registry entry for NCT03895684 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (88% lower). The listed sponsor is Salarius Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 1 intervention - of which SP-2577 Seclidemstat is the first listed.

NCT03895684 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Arizona, California.

Frequently Asked Questions

What is clinical trial NCT03895684 about?

NCT03895684 is a clinical study titled "Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors". Phase 1, open-label, non-randomized dose finding study of SP-2577 in patients with advanced solid tumors.

What is the current status of trial NCT03895684?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2019-06-25. Estimated completion is 2021-04-13.

What conditions does trial NCT03895684 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT03895684?

The interventions under investigation include: SP-2577 Seclidemstat (DRUG).

Who is sponsoring clinical trial NCT03895684?

This trial is sponsored by Salarius Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03895684 being conducted?

This trial has 2 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.